ArticleNature chemical biology2022
A genetic platform to investigate the functions of bacterial drug efflux pumps.
Article in Nature chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Random Forest Modeling to Predict Small Molecule Accumulation in Gram-Negative Bacteria.ACS infectious diseases · 2026Article
- Identifying Antibiotic Effects of Investigational Drugs on Commensal Bacteria with Machine Learning.ACS pharmacology & translational science · 2026Article
- Translation accuracy in E. coli.Nucleic acids research · 2026Article
- A model for drug transport across two membranes of Gram-negative bacteria by an MFS tripartite assembly.Nature communications · 2026Article
- Survival of ampicillin-treated uropathogenic Escherichia coli is independent of single-cell growth rates.npj antimicrobials and resistance · 2026Article
- Loss of DNA mismatch repair genes leads to acquisition of antibiotic resistance independent of secondary mutations.PLoS genetics · 2026Article
- Click-based determination of accumulation of molecules in Escherichia coli.Nature communications · 2026Article
- Genetic Tools and Approaches to Study Bacterial Efflux Pumps.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Energetic and structural control of polyspecificity in a multidrug transporter.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Beyond antibiotic resistance: evidence for resistance-nodulation-division (RND) efflux pumps as virulence determinants.Microbiology and molecular biology reviews : MMBR · 2025Review
- EefR mutations drive sanguinarine resistance by activating cryptic multidrug efflux pumps in AcrB-NullVirulence · 2025Article
- Systematic screen uncovers regulator contributions to chemical cues in Escherichia coli.PLoS biology · 2025Article
- Characterizing Common Factors Affecting Replication Initiation During HInternational journal of molecular sciences · 2025Article
- A historical perspective on the multifunctional outer membrane channel protein TolC in Escherichia coli.npj antimicrobials and resistance · 2025Review
- The AcrAB efflux pump contributes to the virulence of EnteroaggregativeFrontiers in cellular and infection microbiology · 2025Article
- Disruption of the EmrAB-TolC efflux pump ofmicroPublication biology · 2025Article
- Physiological Effects of TolC-Dependent Multidrug Efflux Pumps in Escherichia coli: Impact on Motility and Growth Under Stress Conditions.MicrobiologyOpen · 2024Article
- The complete catalog of antimicrobial resistance secondary active transporters inComputational and structural biotechnology journal · 2024Article
- Structural and functional diversity of Resistance-Nodulation-Division (RND) efflux pump transporters with implications for antimicrobial resistance.Microbiology and molecular biology reviews : MMBR · 2024Review
- The inactivation ofiScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Efflux pumps are a serious challenge for the development of antibacterial agents. Overcoming efflux requires an in-depth understanding of efflux pump functions, specificities and the development of inhibitors. However, the complexities of efflux networks have limited such studies. To address these challenges, we generated Efflux KnockOut-35 (EKO-35), a highly susceptible Escherichia coli strain lacking 35 efflux pumps. We demonstrate the use of this strain by constructing an efflux platform comprising EKO-35 strains individually producing efflux pumps forming tripartite complexes with TolC. This platform was profiled against a curated diverse compound collection, which enabled us to define physicochemical properties that contribute to transport. We also show the E. coli drug efflux network is conditionally essential for growth, and that the platform can be used to investigate efflux pump inhibitor specificities and efflux pump interplay. We believe EKO-35 and the efflux platform will have widespread application for the study of drug efflux.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.